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Tablet dosageAbstract A simple, speciﬁc and accurate isocratic RP-HPLC-DAD method was developed for the
simultaneous determination of phenylephrine, paracetamol, caffeine and chlorpheniramine in bulk
and tablet dosage form. The four contents are present in variable concentrations and have variable
chromatographic behavior making the process of analysis very difﬁcult. For present studies a
reversed-phase C-18 column (150 mm · 4.5 mm i.d., particle size 5 lm) with mobile phase consist-
ing of acetonitrile, methanol and 10 Mm phosphate buffer 16:22:62 (v/v) (pH of buffer 2.5 ± 0.02,
adjusted with ortho phosphoric acid) was used. The ﬂow rate was 1.0 ml/min and eluents were mon-
itored at 280 nm. The mean retention times of phenylephrine, paracetamol, caffeine and chlorphe-
niramine were found to be 1.8, 3.1, 5.2 and 10.9 min, respectively. The method was validated in
terms of linearity, range, speciﬁcity, accuracy, precision and robustness. The proposed method
was successfully applied to the estimation of phenylephrine, paracetamol, caffeine and chlorphenir-
amine in combined tablet dosage form.
ª 2012 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
Paracetamol is analgesic and antipyretic chemically it is N-(4-
hydroxyphenyl) acetamide. Phenylephrine chemically is (1R)-
1-(3hydroxy-phenyl)-2-(methylamino) ethanol hydrochloride
and is used as sympathomimetic (descongestants), chlorphenir-
amine maleate chemically is 3-(4-chlorophenyl)-N, N-di-
methyl-3-pyridin-2-ylpropan-1-amine and is used as an H1-
receptor antagonist (antihistaminic). Caffeine chemically is
(1,3,7-trimethyl-1H-purine-2,6(3H,7H)-dione and acts as a
central nervous system stimulant. Structural formulas of
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Figure 1 The structures of paracetamol (PARA), phenylephrine
hydrochloride (PHE), chlorpheniramine maleate (CPM) and
caffeine (CAF).
Table 1 Precision studies.
Concentration lg/ml Mean measured concentration ±%RSD
Repeatability
(n= 6)
Intermediate precession
(n= 3)
PARA
250 251.60 ± 3.2 250.30 ± 2.5
375 376.60 ± 3.9 374.50 ± 3.2
500 501.40 ± 2.2 502.60 ± 3.3
PHE
7.50 7.40 ± 1.5 7.45 ± 2.5
11.25 11.30 ± 2.3 11.20 ± 2.6
15 15.10 ± 2.5 14.80 ± 3.2
CAF
15 14.90 ± 2.3 14.95 ± 2.8
22.5 22.40 ± 2.8 22.55 ± 3.2
30 30.10 ± 3.2 30.10 ± 2.8
CPM
1 0.95 ± 2.2 1.01 ± 3.5
1.5 1.45 ± 3.2 1.50 ± 3.6
2 1.95 ± 3.8 1.95 ± 3.8
812 A.P. Dewani et al.PARA, PHE, CAF and CPM are given in Fig. 1. These sub-
stances are frequently associated in pharmaceutical formula-
tions against common cold, but are present in formulations
with an important imbalance between the quantities of differ-
ent active ingredients in the dosage forms. Moreover, the ac-
tive compounds have very different polarity and, therefore
chromatographic behavior. The mentioned combination is
available in tablet dosage form as a single unit dose with con-
centration of these active ingredients in varying concentrations
which are as 500 mg of PARA, 15 mg of PHE, 30 mg of CAF
and 2 mg of CPM. The variation of these active ingredients
makes the process of analysis difﬁcult. So far no single HPLC
method is reported to determine the mentioned ingredients
quantitatively in this combination.
The literature reveals number of analytical methods pub-
lished for PARA, PHE, CAF and CPM with some other drug
combinations.
Methods for paracetamol and its combinations in pharma-
ceuticals or in biological ﬂuids have been reported. Paraceta-
mol has been determined in combination with other drugs
using titrimetry (British Pharmacopoeia, 1998; European
Pharmacopoeia, 1997), voltammetry (Saeed and Reyhaneh-Sa-
dat, 2011), ﬂuorimetry (Hossein and Yahya, 2011), colorime-
try (Shihana et al., 2010), UV-spectrophotometry (Ghulam
et al., 2011), quantitative thin-layer chromatography (TLC)
Atul et al., 2008, high-performance liquid chromatography
(HPLC) Prasanna and Reddy, 2009; Godse et al., 2009; Fran-
eta et al., 2002; Godse et al., 2001; Pattan et al., 2009; Gopi-
nath et al., 2007; Olmo et al., 2005 and gas chromatography
(GC) Belal et al., 2009 in pharmaceutical preparations.
An HPLC method for phenylepherine in combination with
chlorpheniramine maleate have been reported (Mukesh et al.,
2010).
Chlorpheniramine maleate has been reported to be quanti-
ﬁed in combination with other active agents by spectropho-
tometry (Khoshayand et al., 2010; Maryam and Mehdi,
2005), HPLC (Sandeep, 2011), LC–MS–MS (Qiongfeng
et al., 2008) and Voltammetric (Shekappa et al., 2011).Caffeine has been quantiﬁed in combination with some
other active agents by variety of analytical methods such as
spectrophotometry (Kuldeep et al., 2011), HPLC (Viswanath
et al., 2011) and HPTLC (Misra et al., 2009).
To our knowledge, the methods described in the literature
do not cover the analysis of the combination PARA, PHE,
CAF and CPM in pharmaceutical formulations. Therefore,
the main objective of this work was to develop a single separa-
tion method for analyzing these four analytes which are pres-
ent in variable concentrations in tablet dosage form.
Within this context, a simple alternative methodology for
determination of these drugs in tablets using an isocratic chro-
matographic mode in analysis time of 15 min was proposed.
After validation of method for various parameters, the method
proved to be successful and was applied to the analysis of com-
mercial products containing these active ingredients.
2. Materials and methods
2.1. Chemicals and reagents
Working standards of pharmaceutical grade phenylepherine
hydrochloride, paracetamol, caffeine and chlorpheniramine
maleate were obtained as generous gifts from Leben pharma-
ceuticals (Akola Maharashtra, India). They were used without
further puriﬁcation. Fixed dose combination tablet Sinarest
(Centaur pharma. ltd) containing 15 mg phenylepherine
hydrochloride, 500 mg Paracetamol, 30 mg caffeine and 2 mg
chlorpheniramine maleate was purchased from local market,
Yavatmal, Maharashtra, India. All the chemicals were of
HPLC grade, purchased from Merck Chemicals, India. Water
used was double distilled and ﬁltered through a 0.45 lm ﬁlter.
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The HPLC system consisted of waters series 600E pump qua-
ternary gradient, waters online degasser module a 996 photo-
diode array (PDA) detector, a 515 autoinjector; data were ac-
quired and processed by use of EMPOWER software (all
equipments from Waters, Milford). The chromatographic sep-
arations were carried out on a C-18 Phenomenex column
(150 mm · 4.5 mm i.d., particle size 5 lm) with isocratic
conditions.
2.3. Preparation of standard stock and sample solution
Preliminarily sample preparation was done in acetonitrile but
analates demonstrated signs of instability behaving variably
with time after injecting them in various chromatographic con-
ditions. Further studies were carried by preparing stock solu-
tion of analates in mixture of phosphate buffer 10 Mm pH
2.5 and acetonitrile (95:5) taking accurately weighed quantity
of PARA, CAF, PHE and CPM transferred to 25 ml volumet-
ric ﬂasks separately to give stock solutions of 250 lg/ml each
of PARA, CAF, PHE and CPM.
For preparation of sample solution of tablets twenty tablets
(Sinarest Tab, Centaur) were weighed and powdered ﬁnely.
Tablet powder equivalent to 2 mg of CPM, 15 mg of PHE,
500 mg of PARA 30 mg of CAF was transferred to a 25 ml
volumetric ﬂask and dissolved in 20 ml of Phosphate buffer
10 Mm pH 2.5 and acetonitrile 95:05. The solution was ultra
sonicated for 15 min and ﬁltered through 0.45 micron mem-
brane ﬁlter. The solutions were further diluted to obtain con-
centration of 60 lg/ml of PHE, 20 lg/ml of PARA, 120 lg/
ml of CAF and 8 lg/ml of CPM. This mixture was subjected
to HPLC analysis in developed chromatographic conditions.
2.4. Chromatographic conditions
The mobile phase consisted of a mixture of acetonitrile: meth-
anol and 10 Mm phosphate buffer pH 2.5 adjusted with ortho
phosphoric acid in the ratio 16:22:62 (v/v) ﬂow rate of 1 ml/
min at isocratic mode the eluants were monitored at 280 nm.
The mobile phase was ﬁltered through 0.45 micron membrane
ﬁlter and degassed before use. The injection volume was 20 ll
and all analyses were performed at ambient temperature.
3. Results and discussion
3.1. Method development and optimization of chromatographic
conditions
In order to optimize the method for drug analysis in pharma-
ceutical formulations, preliminary tests were performed to se-
lect optimal conditions. Parameters such as ideal mobile
phase and their proportions at optimum pH were exhaustively
studied so as to achieve a reasonable degree of separation of
analates. Several binary or ternary eluents were tested using
different proportions of solvent, such as acetonitrile, metha-
nol, water and buffer at different pH conditions. However, sat-
isfactory results were achieved by 16:22:62% v/v/v of
acetonitrile:methanol:phosphate buffer (10 Mm) pH 2.5 ad-
justed with ortho phosphoric acid at ﬂow rate of 1 ml/min fol-
lowed by detection at 280 nm. Fig. 2 shows the chromatogramfor standard mixture obtained through the optimized variables
in accordance with the features described above. Table 3 shows
analytical parameters such as retention time, asymmetry, tail-
ing and theoretical plates obtained for the optimal chromato-
graphic conditions.
3.2. Method validation
3.2.1. Selectivity and linearity
Method selectivity was assessed by the peak purity test (com-
parison between analyte peak and auto threshold in the purity
plot) using diode array detector. The analyte chromatographic
peak was not found to be attributable to more than one com-
ponent indicating the method to be selective (International
Conference Harmonisation, 1995).
For linearity, an external method was used for the simulta-
neous determination of four ingredients. Five concentrations
were chosen ranging from 50% to 150% of the target analyte
concentrations in formulations. So the concentrations were
PARA 250 to 750 lg/ml, phenylephrine hydrochloride 7.5 to
22.5 lg/ml, caffeine 10 to 45 lg/ml and chlorpheniramine male-
ate 1.0 to 3 lg/ml. All the solutions were prepared in Phosphate
buffer (pH 2.5): acetonitrile 95:05. Each point was analyzed
three times (n= 3). Each concentration of standard mixture
solutions was injected in triplicate and the mean value of peak
area was taken for the calibration curve. Calibration graph was
obtained by plotting peak area versus concentration of stan-
dard drugs [Fig. 3 (A), (B), (C) and (D)]. The linear regression
equations for PHE, PARA, CAF and CPM were found to
be y= 527.33x+ 99, y= 84197x+ 92339, y= 14367x+
31023 and y= 9011x+ 745, respectively. The regression coef-
ﬁcient values (R2) were found to be 0.999, 0.999, 0.980 and
0.984, respectively indicating an acceptable degree of linearity.
3.2.2. Speciﬁcity
The speciﬁcity of method was accessed from the chromato-
gram where complete separation of PARA, PHE, CAF and
CPM was achieved and against no potential interferences in
the presence of placebo. The peaks obtained were sharp and
well separated at the baseline. Also excipients from formula-
tion were not interfering with assay. No interferences were de-
tected at retention times of PARA, PHE, CAF and CPM in
sample solution proving the method to be speciﬁc.
3.2.3. Precision
The precision of an analytical method is the closeness of repli-
cate results obtained from analysis of the same homogeneous
sample. Precision is determined through the estimate of the rel-
ative standard deviation (RSD) values. The precision in the
validation of this optimized method was performed at two lev-
els: repeatability and intermediate precision.
Repeatability (n= 6) in sample area was carried out for
100.0% of the test concentration. In the present case, concentra-
tions at 500, 15, 30 and 2 lg/ml for PARA, PHE, CAF and
CPM, respectively were used. Intermediate precision (n= 6)
was performed on different days. All results presented accept-
able precision values (not exceeding 5.00%) as shown in Table 1.
3.2.4. Accuracy
The accuracy of an analytical method is the closeness of results
obtained by that method to the true value for the sample. It is
Figure 2 HPLC chromatogram obtained during simultaneous determination of PHE, PARA, CAF and CPM.
Figure 3 Calibration curves of (A) PHE, (B) PARA, (C) CAF, (D) CPM.
Table 2 Accuracy studies of PHE, PARA, CAF and CPM.
Recovery
level (%)
Std. added
to placebo
Amount
added (mg)
Mean recovery
(mg) ±%RSD (n= 3)
Mean%
recovery
50 PHE 7.5 7.45 ± 2.4 99.33
PARA 250 249.50 ± 2.6 99.80
CAF 15.0 14.95 ± 2.2 99.66
CPM 1.0 0.97 ± 2.6 97.00
100 PHE 15 14.90 ± 2.5 99.33
PARA 500 501.50 ± 2.9 100.30
CAF 30 30.20 ± 2.4 100.66
CPM 2 1.95 ± 2.7 97.50
150 PHE 22.5 22.70 ± 2.6 100.88
PARA 750 753.50 ± 2.5 100.46
CAF 45 45.30 ± 2.3 100.66
CPM 3 3.05 ± 2.4 101.66
814 A.P. Dewani et al.expressed as % recovery determined by standard addition
method. Accuracy was assessed by spiking the active ingredi-
ents into the placebo at different concentrations 50%, 100%,
and 150% each of the labeled claim and injected in developed
chromatographic conditions in triplicate. The recovery data
for accuracy studies is shown in Table 2.Table 3 System suitability studies.
STD. sol. Parameters (*mean values) n= 7
RT* Asymmetry* Tailing* Theoretical plates*
PHE 1.8 1.214 1.107 14942
PARA 3.1 0.841 0.9 13052
CAF 5.2 1.952 1.432 8790
CPM 10.9 2.055 2.528 24214
* = mean value (n = 7).
Figure 4 Robustness studies: for change in pH of buffer. (A) pH 2.4, (B) pH 2.6, (C) pH 2.5.
Table 4 Robustness studies for PHE, PARA, CAF and CPM.
System suitability parameters %RSD of peak area response (n= 3) Mean tailing factor (n= 3) Mean retention time in min (n= 3)
Variations PHE PARA CAF CPM PHE PARA CAF CPM PHE PARA CAF CPM
Change in ﬂow +10 2.8 2.5 2.4 2.6 1.64 1.56 0.95 0.89 2.1 2.82 3.64 7.95
0 2.5 3.2 2.5 2.9 1.1 0.9 1.4 1.5 1.8 2.52 3.34 7.18
10 2.6 3.1 2.4 2.1 1.61 1.61 1.08 0.98 1.52 2.15 3.10 6.60
Change in% Organic
phase (Acetonitrile)
+10 2.70 2.4 3.2 2.9 1.52 1.66 1.34 1.22 2.10 2.75 3.55 7.50
0 2.8 2.3 2.2 2.6 1.2 1.2 1.6 1.3 1.88 2.55 3.40 7.20
10 2.90 2.6 2.8 2.9 1.8 1.8 1.4 1.6 1.90 2.60 3.60 7.10
Change in pH +0.1 2.6 2.9 2.4 2.6 1.5 1.6 1.7 1.2 1.85 2.55 3.36 7.20
0 2.5 2.6 2.4 1.3 1.6 1.4 1.5 1.6 1.90 2.60 3.50 7.20
0.1 2.6 2.4 1.8 1.9 1.5 1.4 1.6 1.5 1.90 2.65 3.30 7.60
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For system suitability parameters, seven replicate injections of
mixed standard solution were injected and parameters such as
the retention time, asymmetry factor, tailing factor and theo-
retical plates of the peaks were calculated. The results are
shown in Table 3.
3.2.6. Robustness studies
Robustness of the developed method was evaluated by deliber-
ate minor modiﬁcations in chromatographic conditions. The
parameters included variation of percentage of organic phase,
for present studies the change in concentration of acetonitrile
in the mobile phase was varied as it was organic solvent in min-
or concentrations in developed chromatographic conditions.
Second parameter was ﬂow rate and third was pH (Fig. 4).
Robustness of the method was checked at concentration levelsTable 5 Analysis of marketed formulation by proposed
method.
Commercial
formulation
Ingredients Labeled
amount (mg)
Amount
found (mg)
Found%
Sinarest tab PHE 15 14.95 99.67
PARA 500 502.60 100.52
CAF 30 30.80 102.66
CPM 2 2.05 102.50500 lg/ml for PARA, 15 lg/ml for PHE, 30 lg/ml for CAF
and 2 lg/ml for CPM. The results of robustness studies are
presented in Table 4. The system suitability parameters consid-
ered for deliberate changes were %RSD of peak areas, mean
tailing factor and mean retention time.
3.2.7. Analysis of formulation
The proposed HPLC method was applied to simultaneous
determination of PHE, PARA, CAF and CPM in Sinarest
Tablet. The quantitative results of these assays are summa-
rized in Table 5. Satisfactory results were obtained for each
compound in good agreement with labeled claims. No interfer-
ences of excipients were seen in chromatogram.
4. Conclusion
A novel RP-HPLC-DAD method has been developed for the
simultaneous estimation of PHE, PARA, CAF and CPM in
bulk and tablet in which the active agents are present in vari-
able concentrations. The problem associated with the present
combination was the variability in chromatographic behavior
of these analates also the variation in concentrations in dosage
forms. The method gave good resolution for all the four drugs
with a short analysis time below 10 min. The developed meth-
od was validated. It was found to be simple, precise, accurate,
and sensitive. The proposed method was speciﬁc as the excip-
ients present in the dosage forms have no interference in the
816 A.P. Dewani et al.determination of the active constituents. The proposed method
can be used for routine analysis of PHE, PARA, CAF and
CPM in combined dosage form which are present in variable
concentrations. It can be also applied in the quality control
of bulk manufacturing of presented API’s.Acknowledgments
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